US FDA panel votes against use of Novo Nordisk's weekly insulin in type 1 diabetes patients-March 2024-www.financetom.com

US FDA panel votes against use of Novo Nordisk's weekly insulin in type 1 diabetes patients

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

US FDA panel votes against use of Novo Nordisk's weekly insulin in type 1 diabetes patients

May 24, 2024 12:56 PM

May 24 (Reuters) - A panel of independent experts to the

U.S. health regulator on Friday voted against the use of Novo

Nordisk's weekly insulin in patients with type 1

diabetes due to risks of low blood sugar.

Previous page： Telos Awarded US Air Force Contract Worth up to $12.5 Billion Next page： Sarepta Therapeutics Insider Bought Shares Worth $4,955,728, According to a Recent SEC Filing

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Telos Awarded US Air Force Contract Worth up to $12.5 Billion

Aug 20, 2024

08:49 AM EDT, 08/20/2024 (MT Newswires) -- Telos ( TLS ) said Tuesday it has been awarded a contract worth up to $12.5 billion for technology infrastructure upgrades at US Air Force bases worldwide, including National Guard and Reserve locations. The multiple award, indefinite-delivery/indefinite-quantity contract to build, operate, and maintain base network infrastructure is expected to be completed by 2034,...

Sarepta Therapeutics Insider Bought Shares Worth $4,955,728, According to a Recent SEC Filing

Aug 20, 2024

08:50 AM EDT, 08/20/2024 (MT Newswires) -- Michael Andrew Chambers, Director, on August 16, 2024, executed a purchase for 37,038 shares in Sarepta Therapeutics ( SRPT ) for $4,955,728. Following the Form 4 filing with the SEC, Chambers has control over a total of 292,311 shares of the company, with 8,277 shares held directly and 284,034 controlled indirectly. SEC Filing:...

Bio-Rad Laboratories Names Jon DiVincenzo COO

Aug 20, 2024

08:50 AM EDT, 08/20/2024 (MT Newswires) -- Bio-Rad Laboratories ( BIO/B ) said Tuesday that it has appointed Jon DiVincenzo as chief operating officer, effective Sept. 9, to succeed Andy Last, who is set to retire. Most recently, DiVincenzo was president of Central Laboratories and International at Labcorp Holdings (LH). Price: 328.49, Change: +2.16, Percent Change: +0.66 ...

Draganfly Down 13% In US Premarket As Prices US$2 Million Registered Direct Offering

Aug 20, 2024

08:50 AM EDT, 08/20/2024 (MT Newswires) -- Draganfly ( DPRO ) , a drone solutions, and systems developer, was at last look down 13% and nearer 52 week lows in US premarket trade on Tuesday as it entered into a securities purchase agreement with a single institutional investor to purchase near 16.7 million units priced at US$0.12 each to raise...